The story of Sildenafil presents a nuanced case for observers in the medicinal sector. While initially a phenomenal success, producing billions, the exclusivity end and the subsequent entry of cheaper competitors have https://pharma885141.fare-blog.com/42169064/the-little-copyright-and-big-pharma-a-hazardous-investment